| Similar Articles |
|---|
 |
The Motley Fool
February 1, 2008
Brian Lawler |
Alexion Looks for a Bigger Niche Alexion Pharmaceutical announces sales of its rare blood disorder medication should expand in 2008.   |
The Motley Fool
May 1, 2008
Brian Lawler |
Soliris Brightens Alexion's Quarter Alexion Pharmaceuticals' lone drug posts gargantuan growth. |
The Motley Fool
June 22, 2007
Brian Lawler |
Novartis' Good Week The pharma receives a pair of positive regulatory decisions. Investors, take note. |
The Motley Fool
January 27, 2006
Stephen D. Simpson |
A Real Triumph for Alexion A powerful clinical result brings FDA approval into sight for this biotech company. Investors, enjoy the day -- this is what makes biotech investing fun and exciting. |
The Motley Fool
December 29, 2011
Brian Orelli |
Too Early for a New Biotech Orphan? Alexion Pharmaceuticals is profitable with a drug on the market. The next logical step in the progression of a biotech is to buy another company to stock the pipeline. |
The Motley Fool
January 5, 2012
Brian Orelli |
Are These Biotech Drug Launches Back on Track? With the annual health-care conference starting up next week, Dendreon and InterMune announced preliminary fourth-quarter sales today. |
The Motley Fool
May 10, 2011
Brian Orelli |
Uncontrolled Crying Over AVANIR's Prescription Data? It's been a slow start, but don't write off this company's pseudobulbar drug just yet. |
The Motley Fool
July 21, 2011
Tim Beyers |
Alexion Pharmaceuticals Shares Popped: What You Need to Know Shares of Alexion Pharmaceuticals rose close to 11% in early trading and touched a new 52-week high of $57.73 a share after the biotech company raised its full-year forecast. |
Chemistry World
May 12, 2015
Phillip Broadwith |
Alexion to buy Synageva for rare disease drugs Rare disease drugmaker Alexion has agreed to buy US biotech Synageva for $8.4 billion in a mix of cash and shares. |
Chemistry World
September 11, 2012
Maria Burke |
Orphan drugs set for 'tremendous growth' A new report by Thomson Reuters offers clear confirmation that developing drugs for rare, or orphan, diseases is economically attractive, despite the smaller patient pool. |
The Motley Fool
February 22, 2006
Stephen D. Simpson |
Axcan Kicked in the Guts The failure of a phase 3 trial puts future growth prospects for Canadian specialty pharmaceutical AxcanPharma in doubt. Investors, take note. |
Fast Company
David Lumb |
Continuing Its Battle With Silicon Valley, The EU Will Probe How Ads Affect Search Results The EU commission is launching a separate investigation into how online platforms list search results and how they use customer data -- all as part of a general plan for a "unified digital market" announced last week. |
The Motley Fool
November 4, 2005
Stephen D. Simpson |
A $99 Biotech Portfolio Can this biotech six-pack pay off for aggressive investors? Acadia Pharmaceuticals... Alexion Pharmaceuticals... Arena Pharmaceuticals... Crucell NV... DOV Pharmaceutical... Millennium Pharmaceuticals... |
Pharmaceutical Executive
June 1, 2011 |
A Lack of Information Why has the EU still not managed to update its rules on information about medicines? |
The Motley Fool
August 17, 2010
Travers & Jayson |
Is Alexion Pharmaceuticals Burning Out? The first step toward finding a promising biotech company is not to figure out whether the science is any good, but to make sure that the company is financially healthy. |
Fast Company
David Lumb |
The European Union Is Preparing To Sue Google, And It Wants A Fight As the The Wall Street Journal reports, Margrethe Vestager wants a landmark case that will set precedent for how tech mega corporations operate in the EU. |
Fast Company
David Lumb |
Europe Unveils Strategy To (Finally) Compete With U.S. Tech Titans After multiple lawsuits aimed at U.S. tech titans, the European Union is proposing a unified digital marketplace for companies in all 28 member states that would compete with the likes of Facebook and Google. |
The Motley Fool
March 23, 2004
Alyce Lomax |
Microsoft Strikes Back The EU seems to want to make an example of Microsoft, and of all the potential candidates this could spell trouble for investors. |
Financial Planning
August 1, 2009
Ilana Polyak |
Critical Care As Congress wrestles with healthcare reform proposals under consideration, Kris Jenner, manager of the T. Rowe Price Health Sciences fund, is faced with just as difficult a task: how to make prudent investments in healthcare that can weather the seismic changes in the offing. |
Fast Company
John Paul Titlow |
The EU Officially Reveals Its Plan To Reduce Silicon Valley's Power In Europe As part of its ongoing effort to reposition its economy, the European Union just formally unveiled plans to unify its fractured markets and take a more aggressive stance toward U.S. tech companies. |
The Motley Fool
August 9, 2011
Brian Orelli |
Give Avanir Some Time It's going to need it. |
Pharmaceutical Executive
October 1, 2014 |
Eruptions on the Drug-Pricing Horizon in Europe An escalating political debate over pharma pricing and reimbursement nears the boiling point. |
Chemistry World
July 29, 2015
Matthew Gunther |
Switzerland R&D spending falls after Horizon 2020 cash freeze This check on Swiss research collaboration on EU-funded projects was in response to a vote that limited EU immigration from other member states. |
